Nautilus Biotechnology Inc Stock Price, News & Analysis

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announced that it will disclose its financial results for the first quarter of 2023 on May 2, 2023, prior to the market opening. Management will host a conference call on the same day at 5:30 a.m. PT / 8:30 a.m. ET to discuss these results, along with business developments and future outlook. This will be streamed live on the company’s website. Nautilus is focused on developing a platform for protein analysis aiming to enhance the field of proteomics and improve human health outcomes.

Nautilus Biotechnology, a leader in single-molecule protein analysis, will participate in the B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics Virtual Conference on April 6, 2023. The management will feature in a fireside chat at 10:30 a.m. Pacific Time. Investors and interested individuals can tune in to a live and archived webcast on the company’s website. Nautilus aims to revolutionize proteomics by enhancing access to the proteome, fostering significant advancements in human health. To learn more, visit www.nautilus.bio.

Nautilus Biotechnology, a life sciences company, announced the selection of three research proposals from leading institutions for its First Access Challenge. This initiative grants early access to Nautilus' innovative single-molecule protein analysis platform. The winning projects focus on:

• Therapeutics for Acute Kidney Injuries by researchers at Buck Institute.
• Pathology of Pulmonary Fibrosis conducted by Brigham Young University.
• Cancer Therapies for Glioma led by the University of Southern California.

Each team will analyze samples and receive travel stipends for conference presentations, boosting Nautilus' commitment to advancing proteomics.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) reported its Q4 and fiscal year 2022 results, highlighting significant advancements in its proteomics platform. The company formed a strategic partnership with TGen to investigate protein targets in DIPG, a rare childhood cancer. Operating expenses increased by 26% to $63.6 million, mainly due to higher headcount and public company costs, leading to a net loss of $57.9 million. However, Q4 expenses were below peak levels, ensuring a cash runway extending into 2025. With cash reserves amounting to $313.6 million, Nautilus looks forward to a commercial launch in 2023.

Nautilus Biotechnology, a leader in single-molecule protein analysis, will participate in the 43rd Annual Cowen Health Care Conference on March 6, 2023. The management team is scheduled for a fireside chat at 11:50 a.m. PT. Interested individuals can access a live and archived webcast on the company’s website. Based in Seattle, Nautilus is focused on revolutionizing proteomics and making its benefits accessible to advance human health. For more information, visit www.nautilus.bio.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announced it will report its financial results for the fourth quarter and full year of 2022 on February 23, 2023, before market open. The company's management will host a conference call at 5:30 a.m. PT / 8:30 a.m. ET to discuss the results, business developments, and future outlook. The live webcast will be accessible through the 'Investors' section of its website. Nautilus is focused on developing a single-molecule protein analysis platform aimed at transforming proteomics and enhancing access to proteome data, which has significant implications for human health and medicine.

Nautilus Biotechnology has announced the opening of a new 7,000-square-foot office in San Diego, California, significantly expanding its operational footprint in one of the largest biotech hubs in the U.S. This facility will support various functions including mechanical engineering and bioinformatics, enhancing the company's capacity for research and development on its advanced protein analysis platform. Nautilus' expansion is aimed at fostering a strong scientific community dedicated to proteome analysis, with existing partnerships including Genentech and Amgen. The company remains focused on advancing its technology despite inherent challenges in product development.

Nautilus Biotechnology has partnered with TGen to investigate protein targets in diffuse intrinsic pontine glioma (DIPG), a rare childhood cancer. This collaboration allows TGen to utilize Nautilus' next-generation proteome analysis platform to explore the epigenetic mechanisms of DIPG by studying proteoform variations at the single-molecule level. The partnership marks Nautilus' fifth early collaboration program, advancing their platform access ahead of a commercial launch in 2024. The collaboration is expected to yield vital insights into DIPG, potentially transforming approaches in cancer research.

Nautilus Biotechnology, Inc. has announced the launch of the First Access Challenge, a research competition in single-molecule proteomics, inviting scientists to submit proposals for early access to its Proteome Analysis Platform. The competition aims to discover new biological insights across various fields, including oncology and immunology. Three winning proposals will be chosen in 2023 to collaborate with Nautilus, receiving analysis of 12 samples and support for publication. Applications are due by February 10, 2023, with winners announced during the US HUPO 2023 Conference in March.